Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

LECLEIR INVESTISSEMENTS PHARMACEUTIQUES : revenue, balance sheet and financial ratios

LECLEIR INVESTISSEMENTS PHARMACEUTIQUES is a French company founded 12 years ago, specialized in the sector Activités des sociétés holding. Based in IFS (14123), this company of category PME shows in 2021 a net income positive of 81 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LECLEIR INVESTISSEMENTS PHARMACEUTIQUES (SIREN 799304274)
Indicator 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C N/C
Net income 80 949 € 130 469 € -13 131 € 38 640 € 40 603 €
EBITDA -3 452 € -8 950 € -4 405 € -2 516 € -2 288 €
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

In 2021, LECLEIR INVESTISSEMENTS PHARMACEUTIQUES generates positive net income of 81 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2021: 41 k€ -> 81 k€.

EBITDA (2021) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-3 452 €

EBIT (2021) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-3 452 €

Net income (2021) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

80 949 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 310%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 24%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 12.3 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.

Debt ratio (2021) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

310.489%

Financial autonomy (2021) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

24.33%

Repayment capacity (2021) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

12.346

Solvency indicators evolution
LECLEIR INVESTISSEMENTS PHARMACEUTIQUES

Sector positioning

Debt ratio
310.49 2021
2019
2020
2021
Q1: 0.13
Med: 15.19
Q3: 84.93
Average

In 2021, the debt ratio of LECLEIR INVESTISSEMENTS P... (310.49) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
24.33% 2021
2019
2020
2021
Q1: 21.52%
Med: 60.87%
Q3: 89.3%
Average

In 2021, the financial autonomy of LECLEIR INVESTISSEMENTS P... (24.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
12.35 years 2021
2019
2020
2021
Q1: -0.0 years
Med: 0.11 years
Q3: 3.68 years
Average +50 pts over 3 years

In 2021, the repayment capacity of LECLEIR INVESTISSEMENTS P... (12.35) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 3581.28. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2021) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

3581.278

Interest coverage (2021) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-252.781

Liquidity indicators evolution
LECLEIR INVESTISSEMENTS PHARMACEUTIQUES

Sector positioning

Liquidity ratio
3581.28 2021
2019
2020
2021
Q1: 108.17
Med: 446.13
Q3: 2343.75
Excellent +21 pts over 3 years

In 2021, the liquidity ratio of LECLEIR INVESTISSEMENTS P... (3581.28) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
-252.78x 2021
2019
2020
2021
Q1: -44.79x
Med: 0.0x
Q3: 0.0x
Average

In 2021, the interest coverage of LECLEIR INVESTISSEMENTS P... (-252.8x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 156 days. Excellent situation: suppliers finance 156 days of the operating cycle (retail model).

Operating WCR (2021) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2021) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2021) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

156 j

Inventory turnover (2021) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
LECLEIR INVESTISSEMENTS PHARMACEUTIQUES

Positioning of LECLEIR INVESTISSEMENTS PHARMACEUTIQUES in its sector

Comparison with sector Activités des sociétés holding

Valuation estimate

Based on 98 transactions of similar company sales in 2021, the value of LECLEIR INVESTISSEMENTS PHARMACEUTIQUES is estimated at 388 014 € (range 131 221€ - 1 096 613€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2021
98 tx
131k€ 388k€ 1096k€
388 014 € Range: 131 221€ - 1 096 613€
NAF 5 année 2021

Valuation method used

Net Income Multiple
80 949 € × 4.8x = 388 014 €
Range: 131 222€ - 1 096 613€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 98 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sociétés holding)

Compare LECLEIR INVESTISSEMENTS PHARMACEUTIQUES with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sociétés holding

Frequently asked questions about LECLEIR INVESTISSEMENTS PHARMACEUTIQUES

What is the revenue of LECLEIR INVESTISSEMENTS PHARMACEUTIQUES ?

The revenue of LECLEIR INVESTISSEMENTS PHARMACEUTIQUES is not publicly disclosed (confidential accounts filed with INPI).

Is LECLEIR INVESTISSEMENTS PHARMACEUTIQUES profitable?

Yes, LECLEIR INVESTISSEMENTS PHARMACEUTIQUES generated a net profit of 81 k€ in 2021.

Where is the headquarters of LECLEIR INVESTISSEMENTS PHARMACEUTIQUES ?

The headquarters of LECLEIR INVESTISSEMENTS PHARMACEUTIQUES is located in IFS (14123), in the department Calvados.

Where to find the tax return of LECLEIR INVESTISSEMENTS PHARMACEUTIQUES ?

The tax return of LECLEIR INVESTISSEMENTS PHARMACEUTIQUES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LECLEIR INVESTISSEMENTS PHARMACEUTIQUES operate?

LECLEIR INVESTISSEMENTS PHARMACEUTIQUES operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.